作者
Alessandro Vitale, Patrizia Burra, Anna Chiara Frigo, Franco Trevisani, Fabio Farinati, Gaya Spolverato, Michael Volk, Edoardo G Giannini, Francesca Ciccarese, Fabio Piscaglia, Gian Lodovico Rapaccini, Mariella Di Marco, Eugenio Caturelli, Marco Zoli, Franco Borzio, Giuseppe Cabibbo, Martina Felder, Antonio Gasbarrini, Rodolfo Sacco, Francesco Giuseppe Foschi, Gabriele Missale, Filomena Morisco, Gianluca Svegliati Baroni, Roberto Virdone, Umberto Cillo, Italian Liver Cancer (ITA. LI. CA) Group
发表日期
2015/3/1
期刊
Journal of hepatology
卷号
62
期号
3
页码范围
617-624
出版商
Elsevier
简介
Background & Aims
The role of hepatic resection for hepatocellular carcinoma (HCC) in different Barcelona Clinic Liver Cancer (BCLC) stages is controversial. We aimed at measuring the survival benefit of resection vs. non-surgical-therapies in each BCLC stage.
Methods
Using the ITA.LI.CA database, we identified 2090 BCLC A, B, and C HCC patients observed between 2000 and 2012: 550 underwent resection, 1046 loco-regional therapy (LRT), and 494 best supportive care (BSC). A multivariate log-logistic model was chosen to predict median survival (MS) after resection vs. MS after LRT or BSC. The results were expressed as net survival benefit of resection: (MS resection – MS LRT)/MS BSC.
Results
After stratifying for BCLC stage, the median net survival benefit of resection over LRT was: BCLC 0 = 62% (40%, 82%), A = 45% (13%, 65%), B = 46% (9%, 76%), C = −16% (−55%, 33%). Model for end-stage liver …
学术搜索中的文章
A Vitale, P Burra, AC Frigo, F Trevisani, F Farinati… - Journal of hepatology, 2015